DMPK and myotonic dystrophy type 1: In line with this, Jauvin et al. demonstrated that targeting DMPK transcripts in DM1 cells and in a mouse model of DM1 with antisense oligonucleotides (ASOs) reduced the number of foci, and improved body weight and muscle strength, without any evident toxicity.56